Teva Pharmaceutical Industries (TEVA) reported Q1 non-GAAP earnings Wednesday of $0.52 per diluted share, up from $0.48 a year earlier.
Four analysts polled by FactSet expected $0.47.
Net revenue for the quarter ended March 31 was $3.89 billion, up from $3.82 billion a year earlier.
Analysts surveyed by FactSet expected $4.06 billion.
The company said its updated full-year 2025 guidance considered the tariff and trade environment as of Wednesday.
Teva now expects 2025 non-GAAP diluted EPS of $2.45 to $2.65, compared with its previous guidance of $2.35 to $2.65. Analysts surveyed by FactSet expect $2.59. Full-year 2025 revenue is now expected to range from $16.8 billion to $17.2 billion, from its previous guidance of $16.8 billion to $17.4 billion. Analysts polled by FactSet expect $17.51 billion.
The company's shares were up 2.1% in recent premarket activity Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。